AtriCure’s (ATRC) “Market Outperform” Rating Reaffirmed at JMP Securities
AtriCure (NASDAQ:ATRC – Get Free Report)‘s stock had its “market outperform” rating reiterated by equities research analysts at JMP Securities in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $60.00 target price on the medical device company’s stock. JMP Securities’ target price indicates a potential upside of 104.85% […]
AtriCure (NASDAQ:ATRC – Get Free Report)‘s stock had its “market outperform” rating reiterated by equities research analysts at JMP Securities in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $60.00 target price on the medical device company’s stock. JMP Securities’ target price indicates a potential upside of 104.85% […]
